The hallmark of this pre-clinical RA period is the detection of specific autoantibodies, particularly those directed towards citrullinated peptide epitopes (anti-citrullinated protein antibodies; ACPA), along with autoantibodies directed towards other post-translational modifications (3, 5, 6). The gene discussed is PRTN3; the disease is rheumatoid arthritis.